Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy (CGT) sector, has reportedly secured nearly RMB 200 million in a Series B financing round. The round was led by 3E Bioventures, with participation from HongSheng Capital and existing investors including Beijing Shuimu Guoding Investment, Tengye Venture Capital, ChangFaZhan, and Shenzhen Angel FoF. The funds raised are earmarked to expedite the commercialization of new, high-quality production equipment.
Established in 2020, Cellbri Bio has been dedicated to the innovation of localized upstream CGT products, catering to the treatment of oncology and chronic diseases.- Flcube.com
